Daily non-political popular news in brief.
Combination therapy improves survival for certain prostate cancer patients
01-22-2008 · EurekAlert!Men with localized prostate cancer who were treated with male hormone suppression therapy and radiation treatment had longer survival, but those with moderate to high levels of other illnesses did not experience this effect, according to a study in the Jan. 23 issue of JAMA.
Read more »
Keywords: combination, therapy, improves, survival, certain, prostate, cancer, patients, improve, patient
« Previous | Next »
Similar news on "Combination therapy improves survival for certain prostate cancer patients":
- Complete response with oblimersen combination improves survival of CLL patients
12-09-2007 · EurekAlert!
Relapsed chronic lymphocytic leukemia (CLL) patients who had a complete response to combination therapy that included the drug oblimersen survived significantly longer than patients treated with chemotherapy alone, a team led by researchers at the University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
Similar news · Read more »
- Bevacizumab found to improve survival for patients with advanced breast cancer
12-26-2007 · EurekAlert!
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
Similar news · Read more »
- Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
- Sunshine pill for prostate cancer in 2009
01-16-2007 · EurekAlert!
A drug based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs could be availiable by 2009. Vitamin D from sunlight improves the prognosis of certain cancers, but taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose.
Similar news · Read more »
- Breast cancer survival rates improved by novel drug sequence, say researchers
02-12-2007 · EurekAlert!
Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
Similar news · Read more »
- New biomarker predicts effectiveness of breast cancer drugs
12-07-2006 · EurekAlert!
University of Cincinnati researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer.Scientists say these findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients.
Similar news · Read more »
- Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »
- Research shows survival benefit for leukemia patients treated with arsenic trioxide
06-04-2007 · EurekAlert!
Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
Similar news · Read more »
- Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
- Personalized diets may offer relief to advanced cancer patients
03-09-2007 · EurekAlert!
Researchers at the University of Alberta studying the effects of chemotherapy and radiation therapy on the senses report that most advanced cancer patients experience unique and persistent taste and smell abnormalities, believed to be a key factor in malnutrition and poor quality of life. Their study suggests that every patient with chemosensory dysfunction has unique symptoms, and a diet tailored to his/her needs would likely improve quality of life.
Similar news · Read more »
